<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="specific treatment is available for emerging viruses such as severe" exact="acute" post="respiratory syndrome coronavirus 2 causing Covid-19. It was aimed"/>
 <result pre="treatment is available for emerging viruses such as severe acute" exact="respiratory" post="syndrome coronavirus 2 causing Covid-19. It was aimed to"/>
 <result pre="is available for emerging viruses such as severe acute respiratory" exact="syndrome" post="coronavirus 2 causing Covid-19. It was aimed to report"/>
 <result pre="Sars-Cov-2 infection. Plasma was collected at least 14 days after" exact="complete" post="recovery from patients who had mild or moderate infection"/>
 <result pre="after complete recovery from patients who had mild or moderate" exact="infection" post="with Sars-Cov-2 infection. The collected CP (200cc) were applied"/>
 <result pre="neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO2 and" exact="total" post="bilirubin values just before and after 1 week of"/>
 <result pre="have older age (74,6 vs 61,85, pâ€‰=â€‰0,018) and more severe" exact="lymphopenia" post="(0,47 vs 1,18, pâ€‰=â€‰0,001). Conclusion CP therapy has the"/>
 <result pre="may be a curative treatment option. Keywords Convalescent plasma Sars-Cov-2" exact="infection" post="Covid-19 Coronavirus Immun plasma 1 Introduction A pneumonia associated"/>
 <result pre="plasma Sars-Cov-2 infection Covid-19 Coronavirus Immun plasma 1 Introduction A" exact="pneumonia" post="associated with acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged"/>
 <result pre="Covid-19 Coronavirus Immun plasma 1 Introduction A pneumonia associated with" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China"/>
 <result pre="Coronavirus Immun plasma 1 Introduction A pneumonia associated with acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1]."/>
 <result pre="Immun plasma 1 Introduction A pneumonia associated with acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1]. The"/>
 <result pre="coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1]. The SARS-CoV-2" exact="infection" post="spread rapidly all over the world. As of June"/>
 <result pre="rapidly all over the world. As of June 12, the" exact="total" post="number of SARS-CoV-2 cases reported by the world health"/>
 <result pre="deaths [2]. There are currently no proven treatment for Coronavirus" exact="disease" post="2019 (Covid-19). There is no effective antiviral drug in"/>
 <result pre="a reliable treatment option for the prevention and treatment of" exact="infectious diseases" post="for more than a hundred years [4]. However, the"/>
 <result pre="the benefit of CP treatment to mortality in Ebola virus" exact="disease" post="has not been showed [5]. Recently, CP was used"/>
 <result pre="effective and reliable treatment option in SARS-CoV-1 and Middle East" exact="respiratory" post="syndrome (MERS) epidemics [6]. Therefore, it suggested that the"/>
 <result pre="and reliable treatment option in SARS-CoV-1 and Middle East respiratory" exact="syndrome" post="(MERS) epidemics [6]. Therefore, it suggested that the use"/>
 <result pre="provides clinical benefit when given early in the course of" exact="disease" post="(ie, in patients who do not require mechanical intubation),"/>
 <result pre="Sars-Cov-2 infection. Plasma was collected at least 14 days after" exact="complete" post="recovery from patients who had mild or moderate infection"/>
 <result pre="after complete recovery from patients who had mild or moderate" exact="infection" post="with Sars-Cov-2 infection. 500â€&quot;600 cc plasma was collected from"/>
 <result pre="before donation to the donors were done before the procedure." exact="Antibody" post="titer was checked before donating to the donors. Plasma"/>
 <result pre="study. Patients with no PCR positivity and strongly suspected Covid-19" exact="disease" post="were excluded from the study. In addition to supportive"/>
 <result pre="differences between parameters before and after CP. The relationship between" exact="disease" post="severity and mortality was analyzed with Fisher's exact test."/>
 <result pre="between the alive and dead patients. pâ€‰ 3 Results A" exact="total" post="of twenty-six Covid-19 patients (8 females and 18 males)"/>
 <result pre="included in the study. Pneumonic infiltration was present in the" exact="chest" post="computerized tomography of all patients. Twenty six patients were"/>
 <result pre="CP. Table 1 Parameters Before CP After CP p value" exact="Leukocyte" post="(Ã—103/Î¼L) 10,15â€‰Â±â€‰4,21 8,86â€‰Â±â€‰4,04 0,455 Neutrophil (Ã—103/Î¼L) 8,75â€‰Â±â€‰4,32 7,23â€‰Â±â€‰3,85 0,346"/>
 <result pre="Lymphocyte (Ã—103/Î¼L) 0,87â€‰Â±â€‰0,63 0,88â€‰Â±â€‰0,67 0,601 Haemoglobin (g/dL) 12,84â€‰Â±â€‰1,74 11,47â€‰Â±â€‰2,03 0,001" exact="Platelet" post="(Ã—103/Î¼L) 244,39â€‰Â±â€‰137,09 221,86â€‰Â±â€‰131,41 0,761 Ferritin (ng/mL) 564,33â€‰Â±â€‰522,19 579,04â€‰Â±â€‰457,25 0,717"/>
 <result pre="ALT (U/L) 36,17â€‰Â±â€‰26,88 82,17â€‰Â±â€‰171,84 0,058 AST (U/L) 46,69â€‰Â±â€‰31,61 91,30â€‰Â±â€‰171,31 0,284" exact="Total" post="Bilirubin (mg/dL) 1,37â€‰Â±â€‰2,33 1,42â€‰Â±â€‰2,80 0,164 CRP (mg/dL) 13,13â€‰Â±â€‰8,59 9,71â€‰Â±â€‰7,35"/>
 <result pre="neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO2 and" exact="total" post="bilirubin values just before and after 1 week of"/>
 <result pre="level in our patients treated with CP was statistically significantly" exact="lower" post="than before CP. The reason for this was thought"/>
 <result pre="CP. The reason for this was thought to be dilutional" exact="anemia" post="due to hydration applied to patients. No severe adverse"/>
 <result pre="have older age (74,6 vs 61,85, pâ€‰=â€‰0,018) and more severe" exact="lymphopenia" post="(0,47 vs 1,18, pâ€‰=â€‰0,001). Table 2 Parameters of alive"/>
 <result pre="patients. Table 2 Parameters Alive (nâ€‰=â€‰20) Dead (nâ€‰=â€‰6) p value" exact="Leukocyte" post="(Ã—103/Î¼L) 9,22â€‰Â±â€‰2,77 11,37â€‰Â±â€‰5,48 0,313 Neutrophil (Ã—103/Î¼L) 7,38â€‰Â±â€‰3,08 10,53â€‰Â±â€‰5,18 0,208"/>
 <result pre="Lymphocyte (Ã—103/Î¼L) 1,18â€‰Â±â€‰0,68 0,47â€‰Â±â€‰0,22 0,001 Haemoglobin (g/dL) 13,11â€‰Â±â€‰1,29 12,54â€‰Â±â€‰2,18 0,661" exact="Platelet" post="(Ã—103/Î¼L) 290,08â€‰Â±â€‰162,19 185â€‰Â±â€‰62,73 0,148 Ferritin (ng/mL) 568,78â€‰Â±â€‰544,26 557,66â€‰Â±â€‰523,99 0,970"/>
 <result pre="ALT (U/L) 36,23â€‰Â±â€‰27,59 36,1â€‰Â±â€‰27,4 0,738 AST (U/L) 37,92â€‰Â±â€‰23,48 58,1â€‰Â±â€‰38,12 0,148" exact="Total" post="Bilirubin (mg/dL) 1,52â€‰Â±â€‰2,52 1,18â€‰Â±â€‰2,19 0,738 CRP (mg/dL) 12,69â€‰Â±â€‰7,72 13,71â€‰Â±â€‰10,01"/>
 <result pre="no specific therapeutic agent for Covid-19 disease. Treatment of the" exact="disease" post="and prevention of its spread are provided by travel"/>
 <result pre="therapy is based on the 1890s used to protect against" exact="bacterial" post="toxins [9]. Intravenous immunoglobulins collected from thousands of healthy"/>
 <result pre="thousands of healthy donors are still used today to prevent" exact="viral" post="infections in some patient populations. CP transfusion has been"/>
 <result pre="of healthy donors are still used today to prevent viral" exact="infections" post="in some patient populations. CP transfusion has been reported"/>
 <result pre="CP transfusion has been reported in the treatment of various" exact="infections" post="over the past decades [10]. In the past two"/>
 <result pre="the 22th day to the other patient. A decrease in" exact="viral" post="load has been shown after CP treatment [14]. Duan"/>
 <result pre="however, it has been observed that it reduces CRP, SARS-CoV-2" exact="viral" post="load and lung lesions in radiological imaging. Compared to"/>
 <result pre="admission to the hospital, symptoms such as an increase in" exact="viral" post="antibody titers, a decrease in SARS-Cov-2 viral loads and"/>
 <result pre="an increase in viral antibody titers, a decrease in SARS-Cov-2" exact="viral" post="loads and normalization of ARDS and fever decreased were"/>
 <result pre="meta-analysis to investigate the effect of CP therapy on Covid-19" exact="disease" post="[7]. They identified the reliability of CP treatment. CP"/>
 <result pre="of CP treatment. CP therapy has been shown to reduce" exact="viral" post="load. Its reliability was demonstrated in China, where it"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751332007143 2WHOWHO coronavirus disease"/>
 <result pre="coronavirus pneumonia in Wuhan, China: a descriptive studyLancet39510223202050751332007143 2WHOWHO coronavirus" exact="disease" post="(COVID-19) dashboard12 June 2020; Available from:2020https://covid19.who.int/?gclid=EAIaIQobChMIz83VtZyC6gIVQuztCh0PrQ3WEAAYASAAEgIFB_D_BwE 3HungI.F.Convalescent plasma treatment"/>
 <result pre="Infect Dis204202039840032113510 5Van GriensvenJ.Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med37412016334226735992 6KoJ.-H.Challenges of convalescent plasma"/>
 <result pre="Med37412016334226735992 6KoJ.-H.Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experienceAntivir Ther237201861762229923831 7BrownB.L.McCulloughJ.Treatment for"/>
 <result pre="in influenzaMil Surg471920177179 10YehK.-M.Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ"/>
 <result pre="influenzaMil Surg471920177179 10YehK.-M.Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ Antimicrob"/>
 <result pre="Surg471920177179 10YehK.-M.Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ Antimicrob Chemother565200591992216183666"/>
 <result pre="14AhnJ.Y.Use of convalescent plasma therapy in two COVID-19 patients with" exact="acute" post="respiratory distress syndrome in KoreaJ Korean Med Sci35142020 15ShenC.Treatment"/>
 <result pre="of convalescent plasma therapy in two COVID-19 patients with acute" exact="respiratory" post="distress syndrome in KoreaJ Korean Med Sci35142020 15ShenC.Treatment of"/>
 <result pre="plasma therapy in two COVID-19 patients with acute respiratory distress" exact="syndrome" post="in KoreaJ Korean Med Sci35142020 15ShenC.Treatment of 5 critically"/>
 <result pre="Plasma Therapy on Time to Clinical Improvement in Patients With" exact="Severe" post="and Life-threatening COVID-19: A Randomized Clinical TrialJAMA2020 18ZhangB.Treatment with"/>
</results>
